VSY Biotechnology to Launch AcrivaUD Trinova Trifocal IOL at ESCRS Meeting

October 6, 2017: By Jon Swedien
VSY's AcrivaUD Trinova Trifocal IOL

VSY’s AcrivaUD Trinova Trifocal IOL

VSY Biotechnology announced Oct. 2 it planned to launch its AcrivaUD Trinova Trifocal IOL at the 2017 meeting of the European Society of Cataract and Refractive Surgeons, being held Oct. 7-11 in Lisbon, Portugal.

The AcrivaUD (Ultra-Definition) Trinova, which has CE mark approval, is manufactured with VSY’s seamless vision technology (SVT).

SVT is a unique patent pending technique to produce an IOL optical surface that does not exhibit any sharp edges, helping reduce halos and scattered light, the company said. The lens shape is derived from sinusoidal functions and results in smoothly, varying surface profiles.

The Netherlands-based firm said the design provides the highest and most optimum light distribution, better contrast sensitivity, and enhanced depth of focus for spectacle independence at all distances.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022